A Retrospective Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus Participants in Southeast Asia
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 70
View:
• Aged greater than equal to (≥) 40 and less than (\<) 70 years
• Male or female
• Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023
Locations
Other Locations
Indonesia
Siloam Hospitals Surabaya
ENROLLING_BY_INVITATION
Surabaya
Siloam Hospitals Lippo Village
NOT_YET_RECRUITING
Tangerang
Malaysia
National Heart Institute
NOT_YET_RECRUITING
Kuala Lumpur
University Malaya Medical Centre
ENROLLING_BY_INVITATION
Lembah Pantai
Philippines
The Medical City Ortigas
NOT_YET_RECRUITING
Pasig
Singapore
Novo Nordisk Investigational Site
RECRUITING
Singapore
Contact Information
Primary
Novo Nordisk
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Time Frame
Start Date: 2026-03-13
Estimated Completion Date: 2026-07-01
Participants
Target number of participants: 400
Treatments
T2DM Cohort
Participants with T2DM identified in south asian countries.
Related Therapeutic Areas
Sponsors
Leads: Novo Nordisk A/S